InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Appoints Experienced Leader as Senior Director of Marketing
April 26, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop optimal cancer therapies, today announced that Theresa Ferguson has been named senior director of marketing. As the company’s senior marketing leader, Ferguson steps in as Predictive Oncology begins commercialization of its knowledge-driven technologies, applying artificial intelligence (“AI”) to develop personalized […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases Year-End 2021 Financial Report, Corporate Update
April 1, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is reporting its financial and corporate results for the year ended Dec. 31, 2021. Highlights of the report include positive results of POAI subsidiary Helomics’ Discovery 21 proof of concept of its PeDAL(R) platform, added revenue […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Calls Validation of Discovery 21 Proof-of-Concept Campaign a ‘Key Milestone’
March 24, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had reached a key milestone toward monetizing its unique approach to leverage AI in oncology drug discovery. The company noted that earlier this year its proprietary Discovery 21 proof-of-concept campaign showed the ability […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Plans to Market Proprietary AI Drug-Discovery Platform
January 27, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is focused on establishing a position as a first mover in the artificial intelligence (“AI”)-powered, drug-discovery market. According to the announcement, the company anticipates the space will reach $20 billion in the next three years. As […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Strong Results from Discovery 2021 Program
January 13, 2022
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today reported the preliminary results of its Discovery 2021 program. According to the update, Predictive Oncology’s Helomics subsidiary’s evaluation demonstrated its proprietary artificial intelligence (“AI”) program CoRE(TM) (Computational Research Engine), combined with its tumor profile data and […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Adjournment of Annual Stockholder Meeting
December 28, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced a new time for its annual meeting of stockholders. The meeting was originally scheduled for Dec. 23, 2021, at 3 p.m. CT, but upon convening was immediately adjourned because a required quorum was not in […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Year-End Shareholder Update
December 21, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today issued a year-end corporate update. Among the highlights, the update discussed POAI’s November 2021 acquisition of zPREDICTA, a cutting-edge cancer based company with a proven commercial and scientific record and patented 3D cell culture platform. “zPREDICTA’s […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Welcomes New SVP of Strategic Sales and Business Development
December 7, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today announced that Pamela Bush, Ph.D., MBA will be joining the company’s leadership team as SVP of Strategic Sales and Business Development. According to the update, Bush brings to POAI’s leadership team nearly two decades of experience […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces zPREDICTA Acquisition
December 1, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, has completed the acquisition of zPREDICTA. According to the announcement, the acquisition provides an immediate new anticipated revenue stream for POAI as well as supporting the company focus on developing new cancer therapies from drug discovery through […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Website Showcasing AI-Driven Advancements in Cancer Research
October 19, 2021
Predictive Oncology (NASDAQ: POAI), an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, today announced the launch of a website that emphasizes its role in advancing its mission. According to the update, the website features information about Predictive Oncology and its subsidiaries, which are […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Approval of Charter Amendment
August 18, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that on Aug. 17, 2021, the stockholders approved an amendment to the company’s certificate of incorporation. The amendment, effective Aug. 17, 2021, increased the number of authorized shares of company common stock from 100,000,000 […]
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary AI Model Predicts Cancer Outcomes, Leads to New Therapies
August 17, 2021
AI models of genomic data can predict cancer outcomes, which can then help personalize ovarian cancer treatments Results come from Helomics’ work on the 100,000 Genomes Project in Genomics England’s National Genomic Research Library Model learns patterns in genetic mutations of patients’ tumors, uses that knowledge to predict patient survival In an historic announcement in […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders
August 11, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs
July 27, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine
July 16, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development […]
InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital
July 9, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending […]
Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries
July 7, 2021
Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kits TumorGenesis will use its GMP lab to […]
Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine
July 2, 2021
Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space Predictive Oncology is strong standout in precision medicine Predictive Oncology (NASDAQ: POAI) has closed on its registered direct […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases
July 2, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology […]
Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference
June 24, 2021
More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021 Companies leveraged different components of the conference to entertain new partnerships or customers Every industry has a revolving calendar of events, but some are […]
Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer
June 22, 2021
Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes. Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform
June 2, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We […]
Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Highlights, Q1 Financials Herald Bright Horizon for Company
May 28, 2021
POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises Company subsidiaries reached several milestone achievements throughout the quarter. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Adds Insight, Strengthens Positioning Through Strategic Board Appointment
May 26, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with health care experience through roles that span clinical medicine, venture capital, health plans, and health […]
InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast
May 18, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share […]
Predictive Oncology Inc. (NASDAQ: POAI) Appoints Venture Investor Dr. Christina Jenkins to Board of Directors
May 18, 2021
POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix Venture Partners, Board Observer for Madorra Inc., board advisory roles at multiple value-generating healthcare companies […]
Predictive Oncology’s (NASDAQ: POAI) C-Level Leaders Provide Company, Operations Update on New Podcast
May 11, 2021
Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO Company anticipates revenue from its unique PeDAL platform Three Predictive Oncology (NASDAQ: POAI) executives were featured guests on a recent Bell2Bell podcast (https://ibn.fm/DumLs). Newly appointed CEO Mel […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing Solutions for ‘Personalized Medicine at Its Finest’
May 6, 2021
Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article. TumorGenesis’ transformational technology enables […]
InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Featured in DojoLIVE! Interview
April 27, 2021
Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief Technical Officer, Mark Collins, PhD, joined the interview to discuss what Helomics is bringing to the table in the field […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Featured in Bell2Bell Podcast
April 21, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Predictive Oncology’s newly appointed CEO, Mel Engle, its CFO, Bob Myers, and CTO of […]
Predictive Oncology’s (NASDAQ: POAI) Subsidiary Refining, Strengthening Personalized Oncology Approach to Ovarian Cancer
April 19, 2021
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of female reproductive system TumorGenesis can provide pharmaceutical companies newfound ability for more effective, expeditious drug development Company is global developer of world-class, innovative technologies using 3D cell culture, media In the treatment of cancer, most patients receive […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Offers Innovative Solution in Multibillion and Growing Market
April 16, 2021
Predictive Oncology (NASDAQ: POAI), through its Skyline Medical division, is positioned for opportunity in the fluid management systems and accessories market, which is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a CAGR of 13.6%. These figures are according MarketsandMarkets, which cites several growth factors including technological advancements in […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expansion of AI-Driven Clinical Models
April 9, 2021
Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used […]
Predictive Oncology Inc. (NASDAQ: POAI) Taps Its Chairman to be CEO
April 5, 2021
Current POAI Chairman J. Melville (“Mel”) Engle has been appointed to CEO position Engle has held executive positions throughout his career at leading pharma and medical device companies, including Dey L.P. (a subsidiary of Merck KGaA), Allergan, Anika Therapeutics and Thermogenesis During his time at Merck’s Dey L.P., Engle transitioned the company from generics to […]
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery
March 30, 2021
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. […]
Predictive Oncology’s (NASDAQ: POAI) Helomics Exec Talks AI, Big Data and Biology During Podcast Appearance
March 29, 2021
Convergence of AI, big data and biology allows Helomics to test drugs on living tumor tissue rather than artificial systems Helomics model evaluates multiple measurements in powerful multi-omics approach to cancer research Knowledge encapsulated by Helomics AI is “gold dust,” says chief innovation officer Data, AI and biology come together at Helomics in a way […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Appoints Board Chair as New CEO
March 23, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and will continue to serve in that role as well as in his new position as […]
Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Working on Gen 3 Fluid-to-Drain Liquid Waste Management System for Hospitals
March 19, 2021
Fluid management systems, accessories market forecast at 13.6% CAGR to $16.1 billion by 2025 Skyline Medical’s STREAMWAY(R) System disrupts today’s standard of manually moving waste fluid for disposal STREAMWAY Systems eliminates waste transport, disposal costs, equipment relocation and risk of exposure to potentially contaminated fluids. For every healthcare facility, particularly hospitals and surgical centers, disposal […]
InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Releases FY 2020 Financial Results, Business Highlights
March 16, 2021
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has reported business highlights and financial results for the year ended Dec. 31, 2020. Highlights discussed in the report include the company’s reinforced balance sheet with net debt and equity offerings for estimated net proceeds of […]
Predictive Oncology Inc. (NASDAQ: POAI) Hits Milestone in AI Platform Development for Ovarian Cancer
March 9, 2021
Cancer screenings, treatments declined during COVID-19 pandemic, highlighting need for personalized therapies to improve outcomes Comprehensive genomic, transcriptomic sequencing of patient samples complete, patient outcome data obtained from UPMC-Magee Project is template for future partnerships with other healthcare institutions to expand POAI’s AI-driven clinical models to other cancers The consequences of COVID-19 sent shock waves […]